treatment of primary astrocytes with a neutralizing anti-ACE2 antibody did not significantly impair SARS-CoV-2 infection, while treatment with anti-NRP1 antibody strongly and significantly blocked infection (Fig. 2E and Fig. S1C). This evidence concerns the gene NRP1 and infection.